Stock Market Reviews

RVPH (Reviva Pharmaceuticals Holdings, Inc.) News

Get the latest news, insights, and market updates on RVPH (Reviva Pharmaceuticals Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
  CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Allia
  Oct 7, 2025 - $RVPH
• Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference
  CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4th Annual
  Oct 2, 2025 - $RVPH
• Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference
  CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor
  Sep 23, 2025 - $RVPH
• Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
  CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 27,000,000
  Sep 19, 2025 - $RVPH
• Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
  CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public off
  Sep 18, 2025 - $RVPH
• RVPH: There May Be A Faster Way
  By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 2Q:25 results, highlighting the June release of the dataset for the open-label extension (OLE) RECOVER trial. In its second quarter report, Reviva announced the possibility of submitting its new drug application (NDA) to the FDA without conducting a second Phase III
  Aug 19, 2025 - $RVPH
• Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
  – Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) – – Planned meeting with Food and Drug Administration (FDA) to discuss brilaro
  Aug 14, 2025 - $RVPH
• Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
  CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 s
  Jun 26, 2025 - $RVPH
• RVPH: Open Label Extension Results & Key Opinion Leader Discussion
  By John Vandermosten, CFA NASDAQ:RVPH Open Label Extension Key Opinion Leader Event Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key opinion leader (KOL) event featuring two luminaries in the schizophrenia space to discuss brilaroxazine and the RECOVER open label extension (OLE) full data set. Dr. Stephen Marder, professor of Psychiatry and Biobehavioral Sciences at UCLA and Dr.
  Jun 5, 2025 - $RVPH
• Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
  CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking p
  Jun 5, 2025 - $RVPH